Published
July 2, 2026
The suit claims Juvederm's warnings never use the word granuloma — and that patients who paid out of pocket for the filler would not have, had the risk of delayed facial lumps been disclosed.
Allegations Only · No Settlement Yet
This article describes a class action complaint. The statements below are unproven allegations. AbbVie Inc. has not been found liable, there is no certified class, and nothing to claim at this time. This page is informational and is not legal advice.
What Is This About?
AbbVie — the pharmaceutical company behind the Juvederm line of hyaluronic acid dermal fillers — is facing a proposed class action lawsuit alleging that it failed to warn patients that the injections can cause granulomas: hard, inflammatory lumps that can appear at the injection site months or even years after treatment, often on the face.The case is captioned Garcia v. AbbVie Inc., Case No. 1:26-cv-07542, and was filed on June 27, 2026 in the U.S. District Court for the Northern District of Illinois, where AbbVie is headquartered. The lead plaintiff, a California pharmacist, says she paid thousands of dollars out of pocket for Juvederm facial injections in 2023 and, three years later, became seriously ill from what the complaint describes as delayed-onset granulomas, requiring hospitalization and multiple medical procedures. AbbVie has not been found liable, and the claims remain unproven.
Status
Complaint Filed
Proposed class action · Garcia v. AbbVie Inc. · N.D. Ill. · Filed June 27, 2026
Allegation
Failure to warn of delayed-onset granulomas
Suit says Juvederm's labeling, warnings, and website never use the word granuloma despite published studies on the risk
Can I Claim?
No — nothing to claim yet
No settlement, no fund, no claim form at this stage
What the Lawsuit Alleges
Juvederm is one of the most widely used dermal fillers in the United States — the complaint cites industry figures of more than 5.2 million hyaluronic acid filler treatments administered in 2023 alone. The filler's active ingredient, hyaluronic acid, occurs naturally in the body. But according to the complaint, the modifications made to stabilize the gel and extend its longevity — including a crosslinking agent called butanediol diglycidyl ether, or BDDE — may trigger delayed inflammatory reactions in some patients as the product breaks down over time.The suit leans on published medical literature, including a 2022 study by Dr. David Funt on delayed-onset inflammatory reactions to hyaluronic acid fillers. That study reported that retrospective chart reviews documented delayed-onset nodules with the Juvederm product family at rates ranging from 0.5% to 0.98% — which the study said was higher than rates seen with other hyaluronic acid fillers. The complaint also points to AbbVie's own premarket testing from more than fifteen years ago, which it says found that 65% to 68% of study subjects experienced lumps and bumps at the injection site, and that 11% to 22% showed nodules, depending on the formulation.
Against that backdrop, the complaint alleges the word "granuloma" appears nowhere in Juvederm's warnings: not in the "WARNINGS" section of the labeling, not in the glossary of terms in the patient materials, and not in the side-effects section of the Juvederm website. The labeling describes "nodules" as a side effect that in most cases goes away within a month — framing the complaint calls misleading, because it says a granuloma is a form of nodule that may not resolve on its own and can allegedly require extensive steroid treatment or surgery, sometimes leaving discoloration, scarring, or disfigurement. As with any complaint, these are allegations only; no court has ruled on whether AbbVie's warnings were inadequate or whether Juvederm is defective.
What Is a Granuloma?
A granuloma, as described by the Cleveland Clinic and cited in the complaint, is an area of tightly clustered immune cells or inflammation that forms around an infection or foreign object. Filler-related granulomas typically present as hard lumps at or near the injection site that may look lighter or darker than the surrounding skin and can be painful to the touch. Because Juvederm is FDA-approved for correcting facial wrinkles and folds, the injection sites — and therefore the alleged lumps — are usually on the face.A central theme of the complaint is timing. It alleges that filler granulomas can appear with significant delay — months or years after an injection — which the suit says makes the alleged omission especially consequential: a patient weighing the treatment today would have no way to connect a future lump to the filler, and no warning telling her the risk exists.
Is There a Juvederm Settlement Yet?
No. Garcia v. AbbVie Inc. is a newly filed lawsuit, not a settlement.That means:
• There is no settlement fund.
• There is no claim form.
• There is no payout, and no deadline to act.
• Juvederm patients do not need to do anything at this stage.
The filing of a complaint is the beginning of a case, not the end. AbbVie has not been found liable simply because a lawsuit was filed. If the case is ever resolved through a settlement, or a class is certified, a formal claims process with its own eligibility rules and deadlines would be announced separately.
Who Could Be Affected?
The complaint proposes four groups: a nationwide class of everyone in the United States who purchased Juvederm filler injections during the applicable limitations period; a nationwide subclass of purchasers who suffered granulomas or delayed-onset granulomas; and matching California classes for state-law claims. No class has been certified, so these definitions are not final and could change.Notably, the suit seeks economic damages — the price premium patients allegedly paid for a product whose risks were not disclosed, along with restitution and disgorgement — rather than functioning purely as a personal-injury case. Juvederm injections are cosmetic and are generally not covered by insurance, so class members would typically have paid out of pocket. If you received Juvederm injections, it may be worth keeping records of your treatments and payments in case a class is later certified. There is nothing to file right now.
Read the Complaint
The full 27-page class action complaint filed in the Northern District of Illinois is embedded below.What Happens Next?
From here, the case moves through the normal early stages of federal litigation. AbbVie may answer the complaint or move to dismiss, the parties may exchange information in discovery, and the plaintiff would eventually ask the court to certify the proposed classes. The suit asserts claims under California's Unfair Competition Law and Consumer Legal Remedies Act, failure-to-warn claims under both strict liability and negligence theories, and unjust enrichment. Any of these steps can take months, and the case could be amended, narrowed, or resolved along the way.Cosmetic and drug-injury failure-to-warn litigation is an active area — related examples on OCA include the Depo-Provera brain tumor lawsuits and the talcum powder cancer litigation. OpenClassActions.com will continue watching the docket for major updates, including a motion to dismiss, class certification activity, or any future settlement or claim form.
Frequently Asked Questions
Is there a Juvederm settlement yet?
No. The case is a proposed class action lawsuit filed on June 27, 2026. There is no settlement, no fund, and no claim form. AbbVie has not been found liable just because a lawsuit was filed.What does the lawsuit allege?
According to the complaint, Juvederm hyaluronic acid fillers can cause granulomas — hard inflammatory lumps that may appear months or years after injection — and AbbVie's labeling, patient materials, and website allegedly omit the word granuloma entirely. The plaintiff claims patients overpaid for a product they would not have purchased had the risk been disclosed. The allegations are unproven.Do I need to file a claim?
No. Because this is a lawsuit and not a settlement, there is nothing to claim and no deadline. If a settlement or certified class ever produces a claims process, eligibility rules and deadlines would be announced then.What should I do if I think I have a granuloma from a filler?
Talk to the medical provider who administered the injection or another qualified physician. Diagnosis and treatment of any lump, swelling, or delayed reaction is a medical question this page cannot answer.Sources
• Class Action Complaint — Garcia v. AbbVie Inc., U.S. District Court for the Northern District of Illinois, Case No. 1:26-cv-07542 (filed June 27, 2026): Complaint (PDF)• U.S. District Court for the Northern District of Illinois — docket for Garcia v. AbbVie Inc., Case No. 1:26-cv-07542, via CourtListener: CourtListener Docket Search
• FDA — "Dermal Filler Do's and Don'ts for Wrinkles, Lips and More," FDA Consumer Updates: FDA Consumer Update
• David K. Funt, "Treatment of Delayed-onset Inflammatory Reactions in Hyaluronic Acid Filler: An Algorithmic Approach" (June 2022): NIH PubMed
• Cleveland Clinic — "Granuloma": Cleveland Clinic
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
For more class actions keep scrolling below.
Status
Complaint Filed — Proposed Class Action
Case Title
Garcia v. AbbVie Inc.
Case Number
1:26-cv-07542
Court
U.S. District Court, Northern District of Illinois
Date Filed
June 27, 2026
Official Court Page
CourtListener Docket
